Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02341638 · ClinicalTrials.gov registry record · Phase 1
Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 1
- Development phase
- 148
- Enrollment target
NCT02341638 is a Phase 1 study that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 148 participants.
The verdict
NCT02341638, a Phase 1 study, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 148 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single and multiple oral doses of BMS-986141 in healthy subjects.
Interventions
- DRUG Placebo
- DRUG Aspirin
- DRUG Itraconazole
- DRUG BMS-986141
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 148 participants |
| Start Date | 2014-09 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02341638
The ClinicalTrials.gov registry entry for NCT02341638 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 148 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT02341638 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02341638 about?
NCT02341638 is a clinical study titled "Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BMS-986141 in Healthy Subjects". The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of a single and multiple oral doses of BMS-986141 in healthy subjects.
What is the current status of trial NCT02341638?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 148 participants. The study started on 2014-09. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02341638?
The interventions under investigation include: Placebo (DRUG), Aspirin (DRUG), Itraconazole (DRUG), BMS-986141 (DRUG).
Who is sponsoring clinical trial NCT02341638?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.